Skip to Content
UW Health SMPH
American Family Children's Hospital
Brad S. Kahl, MD close
Brad S. Kahl, MD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Brad S. Kahl, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Kahl is an Associate Professor of Medicine at the University of Wisconsin. He is the Director of the UW Lymphoma Service and Clinical Research Director for Hematologic Malignancies for the University of Wisconsin Carbone Cancer Center. He received his medical degree from Tufts University, where he was elected AOA. He completed all post-graduate training at the University of Wisconsin. Dr. Kahl is certified by the American Board of Internal Medicine in both Internal Medicine and Hematology. His clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin's lymphoma and chronic lymphocytic leukemia. He is a member of several professional organizations including the American Society of Hematology, the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group.



UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Tufts University School of Medicine, Boston, MA


Madison Magazine Top Docs 2014

Best Doctors® in America 2014

Best Doctors® in America 2013

Madison Magazine Top Docs 2012

Best Doctors® in America 2011

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.


Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.


Dr. Kahl's research focuses on the development of novel treatments for lymphoma patients, with emphasis on the development of targeted therapies. He is the principal investigator of multiple clinical trials at the University of Wisconsin. He serves on the Eastern Cooperative Oncology Group Lymphoma Core Committee and is the principal investigator of ECOG study 4402, Rituximab Extended Schedule or Retreatment Trial (RESORT).

PubMed Articles
Wagner LI Zhao F Hong F Williams ME Gascoyne RD Krauss JC Advani RH Go RS Habermann TM Leach JW O'Connor B Schuster SJ Cella D Horning SJ Kahl BS . Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). J Clin Oncol. 2015 Mar 1;33(7):740-8
[PubMed ID: 25605841]
Kahl BS Hong F Williams ME Gascoyne RD Wagner LI Krauss JC Habermann TM Swinnen LJ Schuster SJ Peterson CG Sborov MD Martin SE Weiss M Ehmann WC Horning SJ . Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014 Oct 1;32(28):3096-102
[PubMed ID: 25154829]
Fletcher CD Kahl BS . Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma. 2014 Oct;55(10):2228-40
[PubMed ID: 24286262]
Casulo C Vose JM Ho WY Kahl B Brunvand M Goy A Kasamon Y Cheson B Friedberg JW . A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Clin Immunol. 2014 Sep;154(1):37-46
[PubMed ID: 24928323]
Rajguru S Kahl BS . Emerging therapy for the treatment of mantle cell lymphoma. J Natl Compr Canc Netw. 2014 Sep;12(9):1311-8; quiz 1318
[PubMed ID: 25190697]
Rajguru S Kristinsdottir T Eickhoff J Peterson C Meyer CM Traynor AM Kahl BS . Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Clin Adv Hematol Oncol. 2014 Aug;12(8):509-15
[PubMed ID: 25356575]
Kahl BS Spurgeon SE Furman RR Flinn IW Coutre SE Brown JR Benson DM Byrd JC Peterman S Cho Y Yu A Godfrey WR Wagner-Johnston ND . A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014 May 29;123(22):3398-405
[PubMed ID: 24615778]
Brown JR Byrd JC Coutre SE Benson DM Flinn IW Wagner-Johnston ND Spurgeon SE Kahl BS Bello C Webb HK Johnson DM Peterman S Li D Jahn TM Lannutti BJ Ulrich RG Yu AS Miller LL Furman RR . Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7
[PubMed ID: 24615777]
Flinn IW Kahl BS Leonard JP Furman RR Brown JR Byrd JC Wagner-Johnston ND Coutre SE Benson DM Peterman S Cho Y Webb HK Johnson DM Yu AS Ulrich RG Godfrey WR Miller LL Spurgeon SE . Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406-13
[PubMed ID: 24615776]
Kahl BS . Bulky aggressive B-cell lymphoma: to radiate or not to radiate--that is the question. J Clin Oncol. 2014 Apr 10;32(11):1097-8
[PubMed ID: 24550422]
Chang JE Li H Smith MR Gascoyne RD Paietta EM Yang DT Advani RH Horning SJ Kahl BS . Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014 Mar 13;123(11):1665-73
[PubMed ID: 24458437]
Chang JE Kahl BS . PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2014 Mar;9(1):33-43
[PubMed ID: 24390602]
Kahl BS Fowler NH Czuczman MS . Integrating emerging treatment options in mantle cell lymphoma. Clin Adv Hematol Oncol. 2013 Dec;11(12 Suppl 19):1-15
[PubMed ID: 24893155]
Stiff PJ Unger JM Cook JR Constine LS Couban S Stewart DA Shea TC Porcu P Winter JN Kahl BS Miller TP Tubbs RR Marcellus D Friedberg JW Barton KP Mills GM LeBlanc M Rimsza LM Forman SJ Fisher RI . Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681-90
[PubMed ID: 24171516]
Oberley MJ Rajguru SA Zhang C Kim K Shaw GR Grindle KM Kahl BS Kanugh C Laffin J Yang DT . Immunohistochemical evaluation of MYC expression in mantle cell lymphoma. Histopathology. 2013 Oct;63(4):499-508
[PubMed ID: 23926923]
Kenkre VP Kahl BS . What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma? Cancer J. 2012 Sep-Oct;18(5):383-9
[PubMed ID: 23006941]
Kenkre VP Kahl BS . The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways. Curr Hematol Malig Rep. 2012 Sep;7(3):216-20
[PubMed ID: 22688757]
Chang JE Kahl BS . Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother. 2012 Jul;13(10):1495-505
[PubMed ID: 22663160]
Chang JE Kahl BS . Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma. 2012 Jul;53(7):1249-50
[PubMed ID: 22220986]
Young EW Pak C Kahl BS Yang DT Callander NS Miyamoto S Beebe DJ . Microscale functional cytomics for studying hematologic cancers. Blood. 2012 Mar 8;119(10):e76-85
[PubMed ID: 22262772]